Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Notice of Acceptance” for clinical trial applications for HY3003 injections.
HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist developed by Hanyu Pharmaceutical in collaboration with Shenzhen Carbon Cloud Zhi Peptide Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Carbon Cloud Peptide”). The project obtained novel polypeptide molecules through artificial intelligence combined with peptide chip technology. Hanyu Pharmaceutical is responsible for pre-clinical research, IND declaration, and subsequent clinical trial development. HY3003 is intended for indications such as weight loss, type 2 diabetes, and metabolism-related steatohepatitis. It is a major innovative drug type deployed by the company in the field of metabolic diseases. The dosage form declared this time is an injection, intended for weight loss indications.
The HY3003 project is an example of in-depth cooperation between Hanyu Pharmaceutical and Carbon Yunzhi Peptide in the field of “AI+ peptides”. The two sides are based on deep complementarity of technology and resources — Carbon Cloud Peptide has the advantages of “silicon-based peptide chip technology” and “AI algorithms”, and is responsible for molecular screening; Hanyu Pharmaceutical has accumulated deep accumulation in peptide drug synthesis, purification, formulation development and clinical transformation, and is responsible for pre-clinical research, IND reporting, clinical trials and product registration declarations, forming a collaborative path combining “AI+ peptide chip screening” with industrial development.